{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:53:46Z","timestamp":1774583626440,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":3955,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.7861\/clinmedicine.13-3-263","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T05:12:54Z","timestamp":1370927574000},"page":"263-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Frontline antibiotic therapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Alasdair","family":"MacGowan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Albur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.13-3-263_bib1","first-page":"226","article-title":"On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae","volume":"10","author":"Fleming","year":"1929","journal-title":"Br J Exp Pathol"},{"key":"10.7861\/clinmedicine.13-3-263_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio.590","article-title":"Antibiotics as probes of biological complexity","volume":"7","author":"Falconer","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.7861\/clinmedicine.13-3-263_bib3","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1056\/NEJMp048246","article-title":"Bacterial meningitis \u2013 a view of the past 90 years","volume":"351","author":"Swartz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-3-263_bib4","series-title":"UNAIDS report on the global AIDS epidemic 2010","year":"2010"},{"key":"10.7861\/clinmedicine.13-3-263_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkp255","article-title":"Has the era of untreatable infections arrived?","volume":"64","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijantimicag.2011.12.006","article-title":"Accelerating resistance, inadequate antibacterial drug pipelines and international responses","volume":"39","author":"Theuretzbacher","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.7861\/clinmedicine.13-3-263_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jac\/dkn357","article-title":"Clinical implications of antimicrobial resistance for therapy","volume":"62","author":"MacGowan","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib9","series-title":"Policy package to combat antimicrobial resistance","year":"2011"},{"key":"10.7861\/clinmedicine.13-3-263_bib10","series-title":"European Antibiotic Awareness Day: 18 November 2011","year":"2011"},{"key":"10.7861\/clinmedicine.13-3-263_bib11","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1128\/AAC.00627-10","article-title":"Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis","volume":"54","author":"Paul","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.7861\/clinmedicine.13-3-263_bib13","unstructured":"13 British Society for Antimicrobial Chemotherapy. www.bsacsurv.org [Accessed 7 April 2013]."},{"key":"10.7861\/clinmedicine.13-3-263_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/dkn355","article-title":"Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007","volume":"62","author":"Farrell","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib15","unstructured":"15 Martin V, Maher K, Morrissey I, Reynolds R,. BSAC respiratory resistance surveillance update 2009\/10. Poster presented at the Federation of Infection Societies (FIS) Scientific Meeting, Manchester, UK, 16\u201318 November 2011 (Poster P0136)"},{"key":"10.7861\/clinmedicine.13-3-263_bib16","series-title":"EARS-Net database","year":"2011"},{"key":"10.7861\/clinmedicine.13-3-263_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jac\/dkp442","article-title":"Reduction in erythromycin resistance in invasive pneumococci from young children in England and Wales","volume":"65","author":"Henderson","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1099\/jmm.0.45763-0","article-title":"Antimicrobial resistance of invasive Streptococcus pneumoniae isolates in a British district general hospital: the international connection","volume":"53","author":"Birtles","year":"2004","journal-title":"J Med Microbiol"},{"key":"10.7861\/clinmedicine.13-3-263_bib19","unstructured":"19 Martin V, Hope R, Livermore DM, Reynolds R,. BSAC bacteraemia resistance surveillance update 2010. Poster presented at the Federation of Infection Societies (FIS) Scientific Meeting, Manchester, UK, 16\u201318 November 2011 (Poster P0135)"},{"key":"10.7861\/clinmedicine.13-3-263_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jac\/dkn354","article-title":"Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06","volume":"62","author":"Brown","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib21","series-title":"Summary points on meticillin resistant Staphylococcus aureus (MRSA) bacteraemia","year":"2012"},{"key":"10.7861\/clinmedicine.13-3-263_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/dkn353","article-title":"Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06","volume":"62","author":"Hope","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib23","unstructured":"23 Reynolds R, Hope R, Warner M,. BSAC bacteraemia resistance surveillance \u2013 no upward creep in MRSA vancomycin MICs. Poster presented at the Federation of Infection Societies (FIS) Scientific Meeting, Manchester, UK, 16\u201318 November 2011 (Poster P22)"},{"key":"10.7861\/clinmedicine.13-3-263_bib24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/dkq009","article-title":"Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK","volume":"65","author":"Kirby","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib25","first-page":"41","article-title":"Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib26","unstructured":"26 Reynolds R, Hope R,. Stabilization in prevalence of ESBLs and ciprofloxacin non-susceptibility in Enterobacteriaceae from blood in the UK and Ireland. Abstract presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 10\u201313 April 2010 (Abstract O135)."},{"key":"10.7861\/clinmedicine.13-3-263_bib27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib28","series-title":"ARMRL news: winter 2012","author":"Woodford","year":"2012"},{"key":"10.7861\/clinmedicine.13-3-263_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cid\/cir838","article-title":"Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia","volume":"54","author":"Pulcini","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib30","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkp404","article-title":"Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins","volume":"65","author":"Wootton","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/dki451","article-title":"Activity of mecillinam against ESBL producers in vitro","volume":"57","author":"Thomas","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkq298","article-title":"Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria","volume":"65","author":"Pallett","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib37","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1128\/AAC.00212-10","article-title":"Use of pristinamycin for infections by Gram-positive bacteria: clinical experience at an Australian hospital","volume":"54","author":"Reid","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/431671","article-title":"Safety of newer parenteral antibiotics","volume":"41","author":"Stein","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.20.1.38","article-title":"BRL 17421 a novel beta-lactam antibiotic highly resistant to beta-lactamases, giving high and prolonged serum levels in humans","volume":"20","author":"Slocombe","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib40","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1164\/rccm.200906-0837OC","article-title":"Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.7861\/clinmedicine.13-3-263_bib42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/dkl017","article-title":"Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK","volume":"57","author":"Gemmell","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib43","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.42.12.3086","article-title":"Ambulatory treatment of multidrug-resistant staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole)","volume":"2","author":"Stein","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib44","unstructured":"44 Kunkel M, Chastre JE, Kollef M, et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus,. Abstract presented at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, BC, Canada, 10\u201313 April 2010 (Abstract LB-49)"},{"key":"10.7861\/clinmedicine.13-3-263_bib45","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.7861\/clinmedicine.13-3-263_bib48","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkr450","article-title":"Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy","volume":"67","author":"Gould","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-3-263_bib51","series-title":"Summary of product characterstics: cubicin powder for concentrate for solution for injection or infusion","author":"Novartis Pharmaceuticals","year":"2012"},{"key":"10.7861\/clinmedicine.13-3-263_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2008.04.009","article-title":"Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia","volume":"61","author":"Tanaseanu","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib55","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.01402-10","article-title":"Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease","volume":"55","author":"Cai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib56","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","article-title":"Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"11","author":"Tasina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/600036","article-title":"Doripenem","volume":"49","author":"Paterson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.13-3-263_bib58","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkr056","article-title":"Comparative activity of carbapenem testing: the COMPACT study","volume":"66","author":"Nordmann","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib59","series-title":"Doripenem in the treatment of hospital-acquired pneumonia","year":"2012"},{"key":"10.7861\/clinmedicine.13-3-263_bib60","series-title":"Antimicrobial stewardship: \u2018Start smart \u2013 then focus\u2019: guidance for antimicrobial stewardship in hospitals (England)","year":"2011"},{"key":"10.7861\/clinmedicine.13-3-263_bib46","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.7861\/clinmedicine.13-3-263_bib47","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824016476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824016476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.13-3-263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:34:31Z","timestamp":1761460471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824016476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1470211824016476"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.13-3-263","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frontline antibiotic therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.13-3-263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2013. All rights reserved.","name":"copyright","label":"Copyright"}]}}